This February, we're excited to shine our Clovertex Target of the Month spotlight on the estrogen...
This April's Clovertex Target of the Month is the Androgen Receptor (AR), a critical protein involved in the development and maintenance of male characteristics and reproductive organs. It is also notably implicated in prostate cancer, where it plays a central role by driving the growth and survival of cancer cells. Targeting AR is therefore a strategic focus for new therapies in oncology, particularly for prostate cancer.
The selection of AR as the Target of the Month follows news of an exclusive strategic license agreement between Novartis and Arvinas for ARV-766, an investigational, orally bioavailable second-generation PROTAC androgen receptor degrader. The comprehensive deal also includes Novartis acquiring Arvinas' preclinical AR-V7 program, positioning Novartis to take over the global clinical development and marketing of ARV-766. Arvinas benefits from an upfront payment of $150m and potential milestone payments of up to $1.01bn, in addition to tiered royalties, marking a pivotal advancement in the pursuit of novel prostate cancer treatments.
The featured rendering displays the crystal structure of human androgen receptor ligand binding domain in complex with testosterone(PDB entry 2AM9).
About Clovertex
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
Useful links
1. Novartis signs deal for Arvinas’ prostate cancer therapy
2. Clovertex website
